Literature DB >> 31088767

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas.

Lu Zhang1, Xiao-Hang Liu2, Fan Jin3, Mei-Xi Liu2, Meng Zhang1, Yan Zhang1, Dao-Bin Zhou1, Wei Zhang4.   

Abstract

BACKGROUND: We studied patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma and measured risk factors suggestive of an underlying lymphoma and follow-up outcomes.
METHODS: CLIPPERS patients associated with or without lymphoma were included into this study. Clinical presentations were documented, risk factors suggestive of an underlying lymphoma were tested, and prognostic differences in terms of death were compared.
RESULTS: Ten patients had a diagnosis of CLIPPERS associated with lymphoma, with 6 B-cell non-Hodgkin lymphoma, 2 T-cell non-Hodgkin lymphoma and 2 Hodgkin lymphoma. Using multivariate logistic analysis, the following 3 independent risk factors were found to be related to a final diagnosis of lymphoma: hyperreflexia (HR 16.56; 95% CI 1.03-265.29; p = 0.032), elevated protein in CSF (HR 11.59; 95% CI 1.24-108.39; p = 0.047), and recurrences between 2 months and 1 year after treatment (HR 29.27; 95% CI 2.09-409.58; p = 0.012). The model calibration was satisfactory (p = 0.392 with the Hosmer-Lemeshow test), and the discrimination power was good (area under the receiver operating characteristic curve 0.921; p < 0.001, 95% CI 0.826-1.000). Patients with CLIPPERS associated with lymphoma had higher mortality rate and lymphoma was a significant predictor of total mortality (HR 0.040; 95% CI 0.006-0.262; p = 0.001).
CONCLUSIONS: Hyperreflexia, elevated protein in CSF and recurrences between 2 months and 1 year after treatment are risk factors suggesting an underlying lymphoma. Relapses during high-dose steroids maintenance therapy can be indicative of lymphoma, too. Patients having CLIPPERS associated with lymphoma have a worse prognosis than those without lymphoma.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids; Clinical characteristics; Lymphoma; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31088767     DOI: 10.1016/j.jocn.2019.04.022

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Area postrema involvement in chronic lymphocytic inflammation with pontine perivascular enhancement.

Authors:  Aigli Vakrakou; Vasilios Constantinides; George P Paraskevas; Kostas Kilidireas; Leonidas Stefanis; Elisabeth Kapaki
Journal:  Neurol Sci       Date:  2020-07-22       Impact factor: 3.307

2.  The Expression of IgG and IgG4 in Orbital MALT Lymphoma: The Similarities and Differences of IgG4-Related Diseases.

Authors:  Kai-Ming Li; Man-Hua Xu; Xia Wu; Wei-Min He
Journal:  Onco Targets Ther       Date:  2020-06-17       Impact factor: 4.147

3.  Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome.

Authors:  Guillaume Taieb; Elsa Kaphan; Claire Duflos; Christine Lebrun-Frénay; Valérie Rigau; Eric Thouvenot; Emeline Duhin-Gand; Romain Lefaucheur; Khe Hoang-Xuan; Sarah Coulette; Jean Christophe Ouallet; Nicolas Menjot de Champfleur; Christine Tranchant; Capucine Picard; Mathieu Fusaro; Fernando E Sepulveda; Pierre Labauge; Geneviève de Saint Basile
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-03-03

4.  Chronic lymphocytic infiltration with pontine perivascular enhancement responsive to steroids (CLIPPERS) and its association with Epstein-Barr Virus (EBV)-related lymphomatoid granulomatosis: a case report.

Authors:  Yew Li Dang; Hong Kuan Kok; Penelope A McKelvie; Matthew Ligtermoet; Laura Maddy; David A Burrows; Douglas E Crompton
Journal:  BMC Neurol       Date:  2021-02-18       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.